Canagliflozin

Overview

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion.

API suppliers (22)

Suppliers of Canagliflozin evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• MATRIX PHARMACORP PRIVATE LTDIndia2 active DMF
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
• BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTDChina1 active DMF
• Shanghai Desano Chemical Pharmaceutical Co., LtdChina1 active DMF
• Macleods Pharmaceuticals Ltd.India1 active DMF GMP on record
• DR REDDYS LABORATORIES LTD1 active DMF GMP on record
• Zhejiang Huayi Pharmaceutical Co., Ltd.China1 active DMF
• INDOCO REMEDIES LTDIndia1 active DMF GMP on record
• CHONGQING CARELIFE PHARMACEUTICAL CO LTDChina1 active DMF
• Zhejiang Huahai Pharmaceutical Co., Ltd.China1 active DMF GMP on record
• Alkem Laboratories LimitedIndia1 active DMF GMP on record
• Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
• DASAMI LAB PRIVATE LTDIndia1 active DMF GMP on record
• Laurus Labs LimitedIndia1 active DMF GMP on record
• Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
• LUPIN MANUFACTURING SOLUTIONS LTD1 active DMF
• Zydus Lifesciences LimitedIndia1 active DMF GMP on record
• FUXIN LONG RUI PHARMACEUTICAL CO LTD1 active DMF
• CHANGZHOU PHARMACEUTICAL FACTORYChina1 active DMF GMP on record
• Jiangxi Synergy Pharmaceutical Co., LtdChina1 active DMF
• Lupin LimitedIndia GMP on record
• Porton Pharma Solutions Ltd.China

Patent & exclusivity (US)

Per the FDA Orange Book (4 approved US products), the latest listed US patent on Canagliflozin expires 26 Aug 2029 and exclusivity 18 Jun 2028. Generic API sourcing typically opens up once these lapse.

Therapeutic areas